Clinical Trial Update: Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating GPC3-targeted CAR T cells armored with IL-15 and IL-21 for GPC3-positive solid tumors; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Embryonal Sarcoma of Liver
• Hepatoblastoma
• Hepatocellular Carcinoma
• Liposarcoma
• Malignant Rhabdoid Tumor
• Rhabdomyosarcoma
• Wilms Tumor
• Yolk Sac Tumor

Drugs mentioned

• GPC3-CAR T cells (IL-15/IL-21 armored)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Hepatoblastoma, Hepatocellular Carcinoma | Phase 1 | Status: RECRUITING